journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer | Page 2

journal
https://read.qxmd.com/read/31097093/epidermal-growth-factor-receptor-targeted-immunomagnetic-liposomes-for-circulating-tumor-cell-enumeration-in-non-small-cell-lung-cancer-treated-with-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors
#21
Shaohua Cui, Yiqian Ni, Yizhuo Zhao, Zonghai Li, Liwen Xiong, Jun Liu, Xiaofei Liang, Liyan Jiang
OBJECTIVES: To establish a circulating tumor cell (CTC) enrichment system for non-small cell lung cancer (NSCLC) patients who received first-line treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKI), using EGFR magnetic liposomes (EGFR-ML). MATERIALS AND METHODS: An inverted evaporation method was used to develop antibody modified EGFR-ML. Peripheral blood was collected from NSCLC patients who underwent first-line EGFR-TKI treatment for CTC enumeration...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097092/clinical-features-and-outcomes-of-pulmonary-lymphoma-a-single-center-experience-of-180-cases
#22
Mu-Chen Zhang, Min Zhou, Qi Song, Shuo Wang, Qing Shi, Li Wang, Fu-Hua Yan, Jie-Ming Qu, Wei-Li Zhao
BACKGROUND: Pulmonary lymphoma arises primarily from the lung, which is extremely rare, or be secondarily involved by lymphoma. The clinical features, management, and prognostic factors have not been clearly identified. METHODS: Sixty-three patients with primary pulmonary lymphoma (PPL) and 117 patients with secondary pulmonary lymphoma (SPL) treated in our institution between June 2003 and December 2017 were retrospectively reviewed. RESULTS: MALT (67%) was the most common pathological subtype of PPL, while DLBCL (48%) was the most common subtype of SPL...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097091/the-metastatic-site-does-not-influence-pd-l1-expression-in-advanced-non-small-cell-lung-carcinoma
#23
H Wang, J Agulnik, G Kasymjanova, P O Fiset, S Camilleri-Broet, M Redpath, V Cohen, D Small, C Pepe, L Sakr, A Spatz
INTRODUCTION: PD-L1 expression by immunohistochemistry (IHC) testing with Tumor Proportion Score (TPS) ≥50% and ≥1% is required to be eligible for first- and second-line Pembrolizumab treatment for metastatic non-small cell lung cancer (NSCLC) respectively. Stage IV NSCLC often presents with metastasis to multiple distant sites which are easily accessible for biopsy. Knowing whether PD-L1 IHC TPS can be indifferently measured from different metastatic site is therefore an important clinical question...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097090/radiomics-signature-a-potential-and-incremental-predictor-for-egfr-mutation-status-in-nsclc-patients-comparison-with-ct-morphology
#24
Wenting Tu, Guangyuan Sun, Li Fan, Yun Wang, Yi Xia, Yu Guan, Qiong Li, Di Zhang, Shiyuan Liu, Zhaobin Li
OBJECTIVES: To compare the predictive performance of radiomics signature and CT morphological features for epidermal growth factor receptor (EGFR) mutation status; then further to develop and compare the different predictive models for EGFR mutation in non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: This retrospective study involved 404 patients with NSCLC (243 cases in the training cohort and 161 cases in the validation cohort). Radiomics features were extracted from preoperative non-contrast CT images of the entire tumor...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097089/the-role-of-radiation-treatment-in-pleural-mesothelioma-highlights-of-the-14th-international-conference-of-the-international-mesothelioma-interest-group
#25
REVIEW
Robert M MacRae, Miranda Ashton, Olivia Lauk, Wesley Wilson, Noelle O'Rourke, Charles B Simone, Andreas Rimner
Radiation remains an important component of mesothelioma treatment in 2018. Its use as a treatment modality continues to evolve as the technology for planning and delivery continues to improve. Use of radiation to improve local control in the involved hemithorax has been a common adjuvant treatment post extrapleural pneumonectomy for many years. Modern treatment options with advanced planning techniques including protons and intensity modulated radiation therapy lead to new potential options for treatment post lung-sparing surgery or in the unresectable setting...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097088/oral-maintenance-metronomic-vinorelbine-versus-best-supportive-care-in-advanced-non-small-cell-lung-cancer-after-platinum-based-chemotherapy-the-ma-ni-la-multicenter-randomized-controlled-phase-ii-trial
#26
Marco Platania, Felice Pasini, Luca Porcu, Mattia Boeri, Francesco Verderame, Yasmina Modena, Alessandro Del Conte, Federico Nichetti, Marina Chiara Garassino, Antonia Martinetti, Elisa Sottotetti, Luigi Cavanna, Emanuela Vattemi, Daniele Pozzessere, Alessandro Bertolini, Luciana Irtelli, Carla Verri, Gabriella Sozzi, Claudia Proto, Ugo Pastorino, Valter Torri, Anna Paola Fraccon, Francesca Spinnato, Diego Signorelli, Giuseppe Lo Russo, Alessandro Tuzi, Rosaria Gallucci, Saverio Cinieri, Manlio Mencoboni, Paola Antonelli, Luca Giacomelli, Filippo de Braud
BACKGROUND: Oral vinorelbine administered at the maximum tolerated dose has already showed activity and a good safety profile in advanced non-small-cell lung cancer (NSCLC). The MA.NI.LA study was a phase II, multicenter, randomized, controlled trial that aimed to assess the effects of a 'switched maintenance' regimen with oral metronomic vinorelbine (OMV) in patients with NSCLC who had not progressed after first-line platinum-based chemotherapy. PATIENTS AND METHODS: Patients were randomly assigned in a 1:1 ratio to either OMV (50 mg three-times weekly) as maintenance treatment or best supportive care (BSC)...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097087/characteristics-of-252-patients-with-bronchopulmonary-neuroendocrine-tumours-treated-at-the-copenhagen-net-centre-of-excellence
#27
V Grøndahl, T Binderup, S W Langer, R H Petersen, K Nielsen, A Kjaer, B Federspiel, U Knigge
BACKGROUND: Bronchopulmonary neuroendocrine tumours are divided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell lung cancer (SCLC). AIM: To thoroughly describe a cohort of 252 patients with TC, AC and LCNEC (SCLC excluded). MATERIAL AND METHODS: Collection of data from 252 patients referred to and treated at Rigshospitalet 2008-2016. Data was collected from electronic patient files and our prospective NET database...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097086/cause-and-effect-relationship-between-fgfr1-expression-and-epithelial-mesenchymal-transition-in-egfr-mutated-non-small-cell-lung-cancer-cells
#28
Johan Vad-Nielsen, Kristine Raaby Gammelgaard, Tina Fuglsang Daugaard, Anders Lade Nielsen
OBJECTIVES: Increased FGFR1 expression is associated with resistance to tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC cells and often concomitant with epithelial to mesenchymal transition (EMT). However, the cause-and-effect relationship between increased FGFR1 expression and EMT in the genetic background of EGFR-mutated non-small cell lung cancer (NSCLC) cells is not clear. Previous studies have specifically addressed the relationship between EMT and increased FGFR1 expression in the context of simultaneous TKI-mediated blocking of EGFR-signaling...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097085/sequencing-of-therapy-following-first-line-afatinib-in-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer
#29
Keunchil Park, Jaafar Bennouna, Michael Boyer, Toyoaki Hida, Vera Hirsh, Terufumi Kato, Shun Lu, Tony Mok, Kazuhiko Nakagawa, Kenneth O'Byrne, Luis Paz-Ares, Martin Schuler, Denis Moro Sibilot, Eng-Huat Tan, Hiroshi Tanaka, Yi-Long Wu, James C-H Yang, Li Zhang, Caicun Zhou, Angela Märten, Wenbo Tang, Nobuyuki Yamamoto
OBJECTIVES: With the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), sequential therapy could potentially render EGFR mutation-positive non-small cell lung cancer a chronic disease in some patients. In this retrospective analysis of EGFR mutation-positive (Del19/L858R) patients receiving first-line afatinib in LUX-Lung 3, 6, and 7, we assessed uptake of, and outcomes following, subsequent therapies including the third-generation EGFR TKI, osimertinib...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097084/comparative-effectiveness-of-multi-fraction-stereotactic-radiosurgery-for-surgically-resected-or-intact-large-brain-metastases-from-non-small-cell-lung-cancer-nsclc
#30
Giuseppe Minniti, Claudia Scaringi, Gaetano Lanzetta, Dimitri Anzellini, Federico Bianciardi, Barbara Tolu, Roberta Morace, Andrea Romano, Mattia Osti, PierCarlo Gentile, Sergio Paolini
PURPOSE: to investigate clinical outcomes in patients with large brain metastases from non-small-cell lung cancer (NSCLC) who received surgical resection and postoperative stereotactic radiosurgery or SRS alone. PATIENTS AND METHODS: Two hundred and twenty-two patients with 241 large brain metastases (2-4 cm in size) who received surgery and multi-fraction SRS (mfSRS) to the resection cavity or mfSRS alone were analyzed. For all lesions the delivered dose was 3 x 9 Gy over three consecutive days...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097083/lung-cancer-incidence-in-female-rises-significantly-in-urban-sprawl-of-shanghai-after-introduction-of-ldct-screening
#31
Fei Liang, Chunxiao Wu, Haiyan Gu, Meiying Zhu, Zeliang Xuan, Yonggen Jiang, Haiquan Chen, Chen Fu, Ying Zheng
OBJECTIVES: LDCT screening for lung cancer has been widely used in China since the release of the NLST trial data in 2011, but little is known about its impact on the incidence and mortality rates of lung cancer in China. METHODS: Official cancer registry data of lung cancer incidence and mortality were collected by Shanghai Municipal Center for Disease Control and Prevention from 2005 to 2014. Two districts (Xuhui and Songjiang Districts) were selected to represent populations with different levels of accessibility to LDCT...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097082/predictive-value-of-serum-protein-levels-in-patients-with-advanced-non-small-cell-lung-cancer-treated-with-nivolumab
#32
Jun Oyanagi, Yasuhiro Koh, Koichi Sato, Keita Mori, Shunsuke Teraoka, Hiroaki Akamatsu, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto
BACKGROUND: Although programmed cell death-ligand-1 (PD-L1) expression in tumor tissue has been established as predictive biomarker for the anti-programmed cell death-1 (PD-1) antibody treatment of non-small-cell lung cancer (NSCLC), additional biomarkers are critically needed. We evaluated serum proteins relevant to immune checkpoint blockade in patients with NSCLC treated with nivolumab to identify novel non-invasive predictive biomarkers. PATIENTS AND METHODS: Patients with advanced NSCLC, who had failed at least one prior chemotherapy regimen, received nivolumab monotherapy (3 mg/kg, Q2W) until progressive disease (PD) or unacceptable toxicity was observed...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31097081/randomized-phase-ii-study-of-pemetrexed-or-pemetrexed-plus-bevacizumab-for-elderly-patients-with-previously-untreated-non-squamous-non-small-cell-lung-cancer-results-of-the-lung-oncology-group-in-kyushu-logik1201
#33
Minoru Fukuda, Takeshi Kitazaki, Daiki Ogawara, Masao Ichiki, Hiroshi Mukae, Riichiroh Maruyama, Noriaki Nakagaki, Midori Shimada, Takaya Ikeda, Junji Kishimoto, Taishi Harada, Takashi Seto, Noriyuki Ebi, Koichi Takayama, Isamu Okamoto, Yukito Ichinose, Kenji Sugio
OBJECTIVES: To evaluate the efficacy and safety, we conducted a randomized phase II study of pemetrexed (Pem) versus Pem + bevacizumab (Bev) for elderly patients with non-squamous non-small cell lung cancer (NSqNSCLC). PATIENTS AND METHODS: The eligibility criteria were as follows: NSqNSCLC, no prior therapy, stage IIIB/IV disease or postoperative recurrence, age: ≥75 years, performance status (PS): 0-1, and adequate bone marrow function. The patients were randomly assigned (1:1 ratio) to receive Pem or Pem + Bev...
June 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31027705/a-retrospective-cohort-study-of-pd-l1-prevalence-molecular-associations-and-clinical-outcomes-in-patients-with-nsclc-results-from-the-european-thoracic-oncology-platform-etop-lungscape-project
#34
Keith M Kerr, Erik Thunnissen, Urania Dafni, Stephen P Finn, Lukas Bubendorf, Alex Soltermann, Eric Verbeken, Wojciech Biernat, Arne Warth, Antonio Marchetti, Ernst-Jan M Speel, Sarawati Pokharel, Anne Marie Quinn, Kim Monkhorst, Atilio Navarro, Line Bille Madsen, Teodora Radonic, Joan Wilson, Graziano De Luca, Steven G Gray, Richard Cheney, Spasenija Savic, Miguel Martorell, Thomas Muley, Paul Baas, Peter Meldgaard, Fiona Blackhall, Anne-Marie Dingemans, Rafal Dziadziuszko, Johan Vansteenkiste, Walter Weder, Varvara Polydoropoulou, Thomas Geiger, Roswitha Kammler, Solange Peters, Rolf Stahel
INTRODUCTION: The PD-L1 biomarker is an important factor in selecting patients with non-small cell lung cancer for immunotherapy. While several reports suggest that PD-L1 positivity is linked to a poor prognosis, others suggest that PD-L1 positive status portends a good prognosis. METHODS: PD-L1 positivity prevalence, assessed via immunohistochemistry (IHC) on tissue microarrays (TMAs), and its association with clinicopathological characteristics, molecular profiles and patient outcome- Relapse-free Survival (RFS), Time-to-Relapse (TTR) and Overall Survival (OS)- is explored in the ETOP Lungscape cohort of stage I-III non-small cell lung cancer (NSCLC)...
May 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31027704/the-role-of-adjuvant-therapy-for-atypical-bronchopulmonary-carcinoids
#35
Rodney E Wegner, Stephen Abel, Shaakir Hasan, Zachary D Horne, Athanasios Colonias, Benny Weksler, Vivek Verma
BACKGROUND: Atypical bronchopulmonary carcinoid tumors are rare but carry high recurrence rates following resection. The role of adjuvant therapy remains unclear owing to a lack of high-volume data. To address this knowledge gap, we examined predictors of adjuvant therapy and effects on outcome. METHODS: We queried the National Cancer Database for patients with resected stage I-III atypical carcinoid. Adjuvant therapy was defined as chest radiation, chemotherapy, or a combination thereof...
May 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31027703/the-presence-and-variant-allele-fraction-of-egfr-mutations-in-ctdna-and-development-of-resistance
#36
Grainne M O'Kane, Geoffrey Liu, Tracy L Stockley, Muqdas Shabir, Tong Zhang, Jennifer H Law, Lisa W Le, Adrian Sacher, Frances A Shepherd, Penelope A Bradbury, Natasha B Leighl
BACKGROUND: Peripheral blood sampling for detection of EGFR T790M in cell-free circulating tumour (ct) DNA in TKI-resistant EGFR mutant (EGFRm) lung cancer is now standard. The value of more comprehensive sequencing is unknown. METHODS: Prospective ctDNA analysis in patients with EGFRm NSCLC was performed using a next generation sequencing (NGS) panel of regions of 11 genes detecting single nucleotide variants and small insertions/deletions at ≥0.1% variant allele frequency (VAF) was performed...
May 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31027702/from-the-beginning-to-resistance-study-of-plasma-monitoring-and-resistance-mechanisms-in-a-cohort-of-patients-treated-with-osimertinib-for-advanced-t790m-positive-nsclc
#37
Paola Bordi, Marzia Del Re, Roberta Minari, Eleonora Rofi, Sebastiano Buti, Giuliana Restante, Anna Squadrilli, Stefania Crucitta, Chiara Casartelli, Letizia Gnetti, Cinzia Azzoni, Lorena Bottarelli, Iacopo Petrini, Agnese Cosenza, Leonarda Ferri, Elena Rapacchi, Romano Danesi, Marcello Tiseo
INTRODUCTION: Analysis of circulating tumor DNA (ctDNA) for the identification of T790M mutation in advanced EGFR-mutated NSCLC patients can replace tissue re-biopsy for resistance characterization and, being non-invasive, may be applied for disease monitoring. We analysed ctDNA during osimertinib treatment to correlate mutational levels with clinical outcome and to predict pattern of resistance. MATERIALS AND METHODS: Forty patients with advanced NSCLC receiving osimertinib for T790M + disease after previous EGFR-TKI were enrolled in a pilot study to collect plasma at baseline and every 12 weeks until progression...
May 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31027701/improvement-in-the-survival-of-patients-with-stage-iv-non-small-cell-lung-cancer-experience-in-a-single-institutional-1995-2017
#38
Natsuki Takano, Ryo Ariyasu, Junji Koyama, Tomoaki Sonoda, Masafumi Saiki, Yosuke Kawashima, Tomoyo Oguri, Kakeru Hisakane, Ken Uchibori, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Fumiyoshi Ohyanagi, Atsushi Horiike, Akihiko Gemma, Makoto Nishio
OBJECTIVES: In the past two decades several antineoplastic agents have been approved for the treatment of advanced non-small-cell lung cancer (NSCLC), and the management of these patients has drastically changed. However, there is limited information regarding the impact of these advances on patient survival in clinical practice. MATERIALS AND METHODS: We analyzed the survival of patients with stage IV NSCLC who received any treatment in the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR) between January 1, 1995 and March 1, 2017...
May 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31027700/comparison-of-alk-detection-by-fish-ihc-and-ngs-to-predict-benefit-from-crizotinib-in-advanced-non-small-cell-lung-cancer
#39
Chen Lin, Xun Shi, Shao Yang, Jun Zhao, Qiong He, Ying Jin, Xinmin Yu
PURPOSE: Anaplastic lymphoma kinase (ALK) is now a validated kinase target in non-small cell lung cancer (NSCLC). We implemented three ALK laboratory methodologies: fluorescence in situ hybridization (FISH), immunohistochemistry (IHC) and next-generation sequencing (NGS) to detect EML4-ALK fusions and compared the predictive value for Crizotinib efficacy in ALK-positive patients. METHODS: 55 ALK positive patients confirmed by at least one method were enrolled in the present study, of whom 45 cases were assessed by FISH, IHC and NGS concurrently, and another 10 cases only received IHC and NGS assessment for ALK status...
May 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/31027699/association-of-baseline-symptom-burden-with-efficacy-outcomes-exploratory-analysis-from-the-randomized-phase-iii-revel-study-in-advanced-non-small-cell-lung-cancer
#40
Maurice Pérol, Katherine B Winfree, Gebra Cuyun Carter, Zhanglin Lin Cui, Lee Bowman, Edward B Garon
OBJECTIVES: The REVEL study demonstrated improved efficacy with ramucirumab plus docetaxel versus placebo plus docetaxel for previously treated advanced/metastatic non-small-cell lung cancer (NSCLC) without further detriment to patient quality of life, symptoms, or functioning. This post hoc analysis explored the association between baseline Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index (ASBI) and efficacy. MATERIALS AND METHODS: Baseline ASBI scores were the average of the 6 LCSS symptom components...
May 2019: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
2
3
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"